 BUFFALO, N.Y., June 25, 2021 GLOBE NEWSWIRE -- 22nd Century Group, Inc. NYSE American: XXII, a leading plant-based biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and hempcannabis research, today released an update letter to its shareholders from CEO James A. Mish. 